Results 41 to 50 of about 11,407 (210)

AmpC β-lactamase induction by avibactam and relebactam [PDF]

, 2017
Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Jamrozy, Dorota, Livermore, David M, Mushtaq, Shazad, Nichols, Wright W, Woodford, Neil, Young, Katherine   +5 more
core   +1 more source

The Surgical Infection Society revised guidelines on the management of intra-abdominal infection [PDF]

, 2017
Background: Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline was released, the plan was to update
Chang, Phillip K, Diaz, Jose J, Jr, Huston, Jared M, May, Addison K, Mazuski, John E, Mollen, Kevin P, Nadler, Evan P, O\u27Neill, Patrick J, Prince, Jose M, Rosengart, Matthew R, Sawyer, Robert G, Tessier, Jeffrey M   +11 more
core   +3 more sources

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria [PDF]

, 2017
Background: Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent ‘enhancer' effect, potentiating β-lactams targeting PBP3.
Livermore, David M, Mushtaq, Shazad, Vickers, Anna, Warner, Marina, Woodford, Neil   +4 more
core   +1 more source

Effectiveness of ceftazidime–avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia [PDF]

International Journal of Infectious Diseases, 2021
Antimicrobial treatments for carbapenem-resistant Enterobacteriaceae (CRE) bacteremia are limited, with colistin-based regimens being a primary therapy. Ceftazidime-avibactam is an emerging treatment for various CRE infections. Our study aimed to assess ceftazidime-avibactam effectiveness compared with colistin in patients with CRE bacteremia.This ...
Hakeam A. Hakeam, Hala Alsahli, Lama Albabtain, Shahad Alassaf, Zainab Al Duhailib, Sahar Althawadi   +5 more
openaire   +3 more sources

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-2016 [PDF]

, 2017
Background: Ceftazidime/avibactam combines an established oxyimino-cephalosporin with the first diazabicyclooctane β-lactamase inhibitor to enter clinical use.
Doumith, Michel, Hill, Robert, Hopkins, Katie L, Livermore, David M, Meunier, Danièle, Pike, Rachel, Staves, Peter, Woodford, Neil   +7 more
core   +1 more source

Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant Klebsiella pneumoniae Strains

Microbiology Spectrum, 2022
A novel Klebsiella pneumoniae carbapenemase (KPC) variant, KPC-93, was identified in two Klebsiella pneumoniae clinical isolates from a patient from China treated with ceftazidime-avibactam.
Yuchen Wu, Xuemei Yang, Congcong Liu, Yanyan Zhang, Yan Chu Cheung, Edward Wai Chi Chan, Sheng Chen, Rong Zhang   +7 more
doaj   +1 more source

WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases [PDF]

, 2017
Background: Several diazabicyclooctanes (DBOs) are under development as inhibitors of Class A and C -lactamases. Inhibition of OXA (Class D) carbapenemases is variable, with those of Acinetobacter spp. remaining notably resistant. We describe a novel DBO,
Anna Vickers, Clinical and Laboratory Standards Institute, David M. Livermore, Neil Woodford, Shazad Mushtaq   +4 more
core   +1 more source

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis [PDF]

Science Advances, 2017
Ceftazidime-avibactam is highly efficacious against extensive- and multidrug-resistant strains of Mycobacterium tuberculosis .
Devyani Deshpande, Shashikant Srivastava, Moti Chapagain, Gesham Magombedze, Katherine R. Martin, Kayle N. Cirrincione, Pooi S. Lee, Thearith Koeuth, Keertan Dheda, Tawanda Gumbo   +9 more
openaire   +2 more sources

Emergence of the New KPC-49 Variant Conferring an ESBL Phenotype with Resistance to Ceftazidime-Avibactam in the ST131-H30R1 Escherichia coli High-Risk Clone

Pathogens, 2021
We report the emergence of an isolate belonging to the sequence type (ST)131-Escherichia coli high-risk clone with ceftazidime-avibactam resistance recovered from a patient with bacteremia in 2019.
Marta Hernández-García, Javier Sánchez-López, Laura Martínez-García, Federico Becerra-Aparicio, María Isabel Morosini, Patricia Ruiz-Garbajosa, Rafael Cantón   +6 more
doaj   +1 more source

KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity [PDF]

Antimicrobial Agents and Chemotherapy, 2020
KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam ...
Poirel, Laurent, Vuillemin, Xavier, Juhas, Mario, Masseron, Amandine, Bechtel-Grosch, Ursina, Tiziani, Simon, Mancini, Stefano, Nordmann, Patrice   +7 more
openaire   +3 more sources